Active Ingredient vs Brand vs Product

An active ingredient is the drug substance responsible for a product’s pharmacologic activity. A brand is a commercial name. A product is the regulated medicine with a specific formulation, route, label, sponsor, indication, market, and approval history.

This distinction is central to obesity-treatment research because the same active ingredient can appear across multiple products, and related products can have different labels, indications, doses, routes, sponsors, markets, payer rules, and commercial roles.

The basic distinction

Term	Practical meaning	Why it matters
Active ingredient	The drug substance, such as semaglutide, tirzepatide, liraglutide, or orlistat	Connects brands, mechanisms, clinical programs, and company portfolios
Brand name	The commercial product name, such as Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Victoza, Xenical, or Alli	Helps readers identify market-facing products without assuming identical labels
Product	A regulated medicine with a specific label, formulation, route, sponsor, and market context	Determines indication scope, approval history, dosing information, and jurisdiction-specific status
Sponsor or authorization holder	The company responsible for regulatory or commercial responsibilities in a jurisdiction	Connects product records to company, licensing, commercialization, and manufacturing context
Manufacturer or commercial partner	A company involved in production, supply, marketing, distribution, or commercialization, depending on the source	Requires role-specific wording because the associated company is not always the physical manufacturer

Ingredient-level records answer one kind of question: which brands, companies, mechanisms, clinical programs, and regulatory milestones connect to a substance. Product-level records answer another: what label, market, route, formulation, indication, approval history, and commercial context applies to a specific medicine.

Common obesity-treatment relationships

Active ingredient	Obesity-treatment product context	Adjacent product context	Why the relationship matters
Semaglutide	Wegovy is Novo Nordisk’s semaglutide product in the US obesity-treatment market	Ozempic and Rybelsus are related semaglutide diabetes products	Links obesity treatment to the wider semaglutide, GLP-1, manufacturing, and cardiometabolic portfolio context
Tirzepatide	Zepbound is Eli Lilly’s tirzepatide product for obesity-related indications in the US market	Mounjaro is the related tirzepatide diabetes product	Links obesity treatment to dual-incretin development and Lilly’s broader tirzepatide portfolio
Liraglutide	Saxenda is Novo Nordisk’s liraglutide product for chronic weight management	Victoza is the related liraglutide diabetes product	Shows how an earlier GLP-1 product family connects obesity and diabetes-market histories
Orlistat	Xenical is the prescription orlistat product	Alli is a lower-dose nonprescription orlistat product	Connects the same ingredient to prescription and over-the-counter distribution contexts

These relationships make adjacent diabetes or nonprescription products relevant to obesity-treatment mapping. They do not make every adjacent product part of the core database, and they do not imply that products with the same ingredient can be read as the same medicine.

Why product identity is more specific than ingredient identity

Product identity carries details that an ingredient name alone cannot supply. A product record may need to specify the brand, dosage form, route of administration, strength, approved indication, label date, sponsor, approval pathway, market, supply status, and commercialization relationship.

For example, semaglutide is the shared ingredient, but Wegovy, Ozempic, and Rybelsus are different products with different market roles and label contexts. Tirzepatide is the shared ingredient, but Zepbound and Mounjaro are not interchangeable database entries.

Company relationships

Company relationships also require precision. The developer, manufacturer, sponsor, distributor, commercialization partner, marketing authorization holder, and current corporate owner may not always be the same entity. For early hub pages, relationship wording should stay dated and source-backed unless a current role has been checked against a label, regulatory record, annual report, or company disclosure.

This matters for acquisitions, licensing agreements, co-commercialization deals, regional launches, manufacturing partnerships, and supply-chain records. A product name alone does not fully explain who controls development, production, regulatory responsibility, or market access in a specific jurisdiction.

Weight loss drug manufacturer and commercial partner records apply this distinction to obesity-treatment products such as Wegovy, Zepbound, Saxenda, Qsymia, Contrave, Xenical, and Alli.

Compounded and non-branded contexts

Active ingredient names can also appear in compounded, non-branded, or supply-chain contexts. Those uses should be handled carefully. An active ingredient name does not by itself establish that a product is the same as an approved branded medicine, has the same label, follows the same manufacturing controls, or carries the same regulatory status.

When compounded or non-branded records are added, they should distinguish ingredient, formulation, source context, regulatory status, jurisdiction, and date.

What not to infer

Shared active ingredient does not mean identical label, indication, dose, route, formulation, delivery device, supply status, reimbursement, commercial availability, safety profile, or patient suitability. Product-specific records should be read with their own source context.